Internet Drug
Pharmaceutical News & Information; Updated Daily

Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
¿Your Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

9/23 Stat's Investigative Reporting Pays Off; Court Documents Reveal Abbott's Role In OxyContin Promotion
Secret trove reveals bold 'crusade' to make OxyContin a blockbuster .... But the role of Abbott in pushing the drug has largely escaped notice. The documents reveal it was a crucial partner in the aggressive — and misleading — selling of OxyContin during its first decade on the market. .... Stat

9/23 Sales Growth Slows in Emerging Markets
Hard to swallow: emerging markets get tougher for drugmakers .... Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent .... Reuters/Ben Hirschler

9/23 "Possibly Effective" Acne Cream Now At $10,000
The newest pharma villain Novum is charging $9,561 for a tube of skin cream .... Aloquin is used to treat acne and eczema, and is made with ingredients that can be bought at a pharmacy for less than $40, according to the FT. The US Food and Drug Administration calls it "possibly effective." .... Quartz

9/23 Eteplirsen Will Be Covered Despite Skepticism on Efficacy
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug .... Payers are "always fumbling to reimburse [for rare disease drugs] as quickly as possible," said RBC Capital Markets analyst Simos Simeonidis, noting that the budget hit to any one payer from such a small patient group is better than an avalanche of bad publicity .... Xconomy

9/23 "Watchdogs Are Being Turned Into Lapdogs": Embargos Used to Control Reporters
How the FDA Manipulates the Media .... The U.S. Food and Drug Administration has been arm-twisting journalists into relinquishing their reportorial independence, our investigation reveals. Other institutions are following suit .... Scientific American

9/23 Celgene's New Indications for Abraxane Will Drive Growth Despite Generic Competition
Glenmark takes aim at Celgene's Abraxane with complex generic deal .... Glenmark has just signed a licensing deal with U.S. firm Particle Sciences for a generic version of Abraxane--an albumin-bound injectable formulation of paclitaxel--and says it plans to start filing the generic in 2019, starting with the U.S. market .... Fierce Pharma

9/23 State AGs Sue Suboxone Maker
Opioid Treatment Maker Accused of Illegally Blocking Generics .... The U.K. pharmaceutical company behind one of the best-selling treatments for opioid addiction -- a growing epidemic across the U.S. -- was sued by 36 states that claim it ripped off consumers by blocking a cheaper generic version of the drug .... Bloomberg

9/23 SNY Needs a Deal to Cover Diabetes Market Losses; May be Eyeing Regeneron
New Setback for Sanofi's Lantus Increases Need for M&A .... Sanofi has lost another round of its battle against generic interlopers in its key diabetes franchise, increasing the urgency for the French pharmaceuticals company to buy or launch new products following its failed run at oncology specialist Medivation .... The Street

9/23 It Usually Costs $800 to Find a Patient for a Parkinson's Study. On Facebook, You Can Find One for $35
The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study .... The MJFF's Facebook recruitment program, launched in January, is targeting participants based on their Facebook interests and preferences, ages, and proximity to metro areas with clinical study sites.... if Facebook members had interests associated with Judaism or Parkinson's disease, they were likely to have an ad about the clinical study pop up on their Facebook pages .... MM&M

9/23 Counterfeit Viagra Factory Shut Down in Poland
Polish police smash 'world's largest' fake Viagra plant .... A police swoop on a house near Bydgoszcz turned up machines worth a million euros installed in secret rooms that could only be accessed through hidden passages. .... Medical Xpress

9/23 Internet Drug News Fast Takes:
The Women's Health Issue No One Talks About
Kaiser Health News
Anthem, Cigna Have Accused Each Other of Merger Breach
Lundbeck says Alzheimer's drug fails in late-stage study
Drugs Can't Cure Alzheimer's. Could They Prevent It?
Bloomberg View
Potentially harmful chemicals widespread in household dust
George Washington University Milken Institute School of Public Health

9/22 Califf Calls for Retraction of Study That Was Basis for Eteplirsen Approval
Amid controversial Sarepta approval decision, FDA head calls for key study retraction .... In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients .... Retraction Watch

9/22 Lantus Out, Basaglar In at UnitedHealth
UnitedHealth trims drug coverage, including Sanofi insulin .... UnitedHealth said it is changing reimbursement terms for long-acting insulins and will no longer cover Lantus, the main insulin drug sold by Sanofi.... Basaglar, a cheaper biosimilar insulin sold by Eli Lilly & Co would be covered as "Tier 1" .... Reuters

9/22 Invokamet XR Approved
FDA Approves Invokamet XR for Treatment of Adults With Type-2 Diabetes .... Invokamet XR is a once-daily, fixed-dose combination of canagliflozin (Invokana), the most-prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, and an extended-release formulation of metformin .... PTCommunity

9/22 GSK Sticking to Antibiotics Research; A Facility Tour and Interviews with Principal Scientists
Why Superbugs Are Beating Big Pharma .... Just this month, AstraZeneca became the latest big pharmaceutical company to pull out of antibacterial drug development when it sold its antibiotics business to Pfizer Inc. GlaxoSmithKline is one of the few big players that's kept at it, sinking about $1 billion of its own money over the past decade into antibacterial research .... Bloomberg
See also: CDC: Too Many Antibiotics Still Being Prescribed in US [HealthDay]

9/22 $20 Billion in Cash in Its Pocket; Takeda Looking for Deals
Takeda's Biotech M&A Menu Is Long, Complex .... Takeda, Japan's largest pharma firm, is willing to spend up to $20 billion on acquisitions overseas .... Bloomberg Gadfly

9/22 Reuters 'Botox Police' Article Spurs Congressional Inquiry
House Committee probes FDA's criminal office after 'Botox Police' complaints .... In a Sept. 20 letter, committee chairman Fred Upton and Subcommittee on Oversight and Investigations chairman Tim Murphy posed a list of questions--including why the criminal office's director, George Karavetsos, runs the unit from a South Florida office near his home--to be answered by Oct. 12 .... Fierce Pharma

9/22 If You Like to Take a Flyer on a Drug Stock...
3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions .... Aerie Pharmaceuticals, Flexion Therapeutics, and Puma Biotechnology may have more running room ahead if regulators give their drugs the go-ahead. .... Motley Fool

9/22 Step Aside, Dr. Watson, Hanover is Here to Mix Cancer Cocktails
Microsoft Develops AI to Help Cancer Doctors Find the Right Treatments .... A Microsoft Research machine-learning project, dubbed Hanover, aims to ingest all the published research papers on cancer and help predict which drugs and which combinations are most effective .... Bloomberg

9/22 21st Century Cures Will Wait Till After Nov. 8
Medical cures bill pushed back to lame-duck .... House Energy and Commerce Committee Chairman Fred Upton is not planning to introduce a new version of his 21st Century Cures Act before the recess after all.... he is still hoping to get the legislation passed in the lame duck session .... The Hill

9/22 Real World Harvoni Price Averages $50,400 in U.S.
Surprise: Gilead's hep C wonder Harvoni costs less in U.S. than in EU, Japan .... According to a report from the IMS Institute for Healthcare Informatics, the combo drug Harvoni may have made its U.S. debut at a list price of $94,500, but after tough negotiations with payers, its net price comes to $50,400. .... Fierce Pharma

9/22 Blame on the Rebates
Blame Game: The $130 Billion in Fees Mylan Says Pushes Up Prices .... Rebates have more than doubled in four years to an estimated $100 billion to $130 billion today in the U.S. .... Bloomberg

9/22 Internet Drug News Fast Takes:
AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy
More Child Suicides Are Linked to A.D.D. Than Depression, Study Suggests
NY Times
Seniors still lagging in use of internet health resources
Reuters Health
Prescription painkillers are more widely used than tobacco, new federal study finds
Washington Post
Smoking Permanently Damages Your DNA
NBC News

9/21 First Female Head of Major Pharma Company
GlaxoSmithKline names insider Emma Walmsley as new CEO .... Walmsley, 47, joined Britain's biggest drugmaker in 2010 from L'Oreal and will replace Andrew Witty, who had previously announced his decision to retire on March 31, 2017 .... Reuters

9/21 Severe Fatty Liver Disease: Hot New Investment Area
Allergan Buys Liver Drug Maker Tobira, Sending Biotech Stocks Up .... Investors bet that buyers will emerge for other companies developing experimental treatments for a liver disease known as NASH. NASH, or non-alcoholic steatohepatitis, is a severe type of fatty liver disease that has become one of the hottest areas in biotech .... Bloomberg
See also: Allergan Buys Two Liver Disease Companies in Less Than a Day [Bloomberg]

9/21 Could Part D Direct Price Negotiations Really Work? A Look at the Chances
The Politics of Medicare and Drug-Price Negotiation .... The idea of authorizing Medicare Part D to negotiate directly with drug companies has received considerable media attention over the past few months and has broad public support, reflected in a recent poll showing 87 percent of Americans have a favorable view of the idea. .... Health Affairs

9/21 Carrey Denies Role in Abuse Death
Jim Carrey Lawsuit Shines Light On Prescription Drug Addiction in U.S. .... A new lawsuit claims actor Jim Carrey used his "immense wealth and celebrity status" to illegally obtain and distribute potentially deadly substances to his girlfriend Cathriona White, who died of a suicidal overdose at age 30 last year .... NBC News

9/21 Pulitizer-Prize Finalist Pharma Reporter Spent Hours Reading Internal FDA Documents Re: Sarepta, And Here's What He Found
Behind the Sarepta drug approval was intense FDA bickering .... "Woodcock's extensive, early involvement in the review process [was] troubling. Indeed, her involvement here appears to have upended the typical review and decision-making process." .... Stat/Pharmalot/Ed Silverman

9/21 13 Major Pharma Companies Pledge to Fend Off Superbugs
Drugmakers pledge to clean up antibiotic factories, curb overuse .... The group will work with independent experts to set new factory standards and review supply chains to ensure antibiotic waste does not enter waterways, where it can lead to the breeding of superbugs. .... Reuters

9/21 Repatha Shown to Kill Plaque. Meanwhile 2 out of 3 Prescriptions Are Denied by Payers
Amgen cholesterol drug reduces arterial plaque buildup .... In the 78-week study of 968 heart patients already on optimum statin therapy, Repatha lowered the percentage of atheroma volume in coronary arteries and demonstrated some plaque regression. .... Reuters

9/21 Painkiller Makers Fighting State by State to Protect Their Sales
Despite crisis, drugmakers work nationwide to fight opioid limits .... The makers of prescription painkillers have adopted a 50-state strategy that includes hundreds of lobbyists and millions of dollars in campaign contributions to help kill or weaken measures aimed at stemming the tide of prescription opioids .... USA Today

9/21 Promising New DPP-4 Inhibitor
Gemigliptin, metformin combo beats monotherapy in T2DM .... Researchers found that from baseline to week 24 the mean changes in HbA1c were −2.06 percent, −1.24 percent, and −1.47 percent, respectively, in the combination, gemigliptin monotherapy, and metformin monotherapy groups .... Medical Xpress

9/21 "Just One Pharmacy Pickup Per Month" Plan Improves Adherence
CVS Health's ScriptSync shows results .... Preliminary results, which tracked enrolled patients’ average days with medication per month using pharmacy claims data, indicated that the service improves medication adherence by an average of 5% to 10% .... Chain Drug Review

9/21 Internet Drug News Fast Takes:
Ariad Shares Rise Amid Speculation of Potential Buyout
Walgreens launches teledermatology service
Chain Drug Review
Employer Premiums Higher Than ACA Rates
Morning Consult
Bayer Raises Peak Sales Forecast for New-Medicine Portfolio
Hospitals Increasingly Employing Doctors, Effects on Care Uncertain

9/20 FastTakes
Amgen-UCB bone drug Romosozumab cuts fractures in osteoporosis for older women
Fierce Biotech
Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement
The Street
GSK cuts vaccine price for refugees, bowing to pressure
Key Insights on Drug Prices and Manufacturer Rebates from the New 2015 IMS Report
Drug Channels

9/20 FDA Approves Duchenne Drug;  Despite Expert Panel Rejection
- Social media pressure trumps science; drug will cost $300K a year
F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For …  even as it approved the drug, the agency also required the company to conduct another clinical trial to confirm the drug's effectiveness. If the drug maker fails to prove it, the agency said it may "initiate proceedings to withdraw approval. …[NY Times]
See Also: Sarepta to charge $300K for Duchenne drug. 'We tried to be reasonable,' CEO says
See Also: Did the FDA set 'a dangerous precedent' with its latest drug approval? … [Stat News]

Jimmy Kimmel Mocks Epi Pen Price During Emmys
Jimmy Kimmel made a hilarious jab at the skyrocketing price of EpiPens while handing out PB&Js at the Emmys … made 7,000 peanut butter and jelly sandwiches, which he then passed out to the audience … "If you're allergic to peanuts, well I guess this is goodbye, because we can only afford one EpiPen …[Business Insider]

Kardashians Begin Labeling Diclegis Social Media Posts As Advertisements
- Posts been masquerading as plain old postings
With FTC on alert, Kardashians back down on rule-skirting social media plugs … Kardashian first got in trouble with the FDA last summer for an Instagram paid post about Diclegis that wasn't labeled as a paid ad and also neglected to give risk and benefit information …[Fierce Pharma]

Valeant: We Didn't Lie: You Will Soon Get Your Rebates
Valeant: rebates on heart drugs are coming … report from Bloomberg last week said many hospitals had yet to receive any relief from the sharply increased prices on the medicines … issued a statement indicating the rebates would be realized first by group purchasing organizations representing hospitals …[Biopharma Dive]

Rep Access To Docs Continues To Plummet
Pharma's access to docs declines as nonpersonal promotion increases … Only 44% of physicians surveyed by ZS said they will meet with sales reps. This is down slightly from 46% in 2015 -- and significantly from 80% in 2008 …[Medical Marketing & Media]

Tylenol Caused My Liver Failure Trial Delayed Again
Bellwether in Tylenol MDL Postponed Again …  wrongful death action filed by plaintiff Rana Terry, whose sister, Denice Hayes, died of liver failure in 2010, ­allegedly caused by consuming Tylenol … more than 50 years of use and over 150 studies to support its safety …[The Legal Intelligence]

Fast Takes
New NIH Rule: Drugmakers Must Report Clinical Trial Results Once Kept Secret
FDA chastises companies for touting an unapproved opioid painkiller Remoxy ER (Oxycodone)
4 ways for marketers to differentiate their brands in the rare-disease space
Novo pulls 71,000 kits of glucagon med from US market
Biopharma Dive
Amgen, Novartis celebrate promising migraine data, but Teva and Alder are preparing to crash the party
Lilly takes one step closer to first-ever approval for new sarcoma drug
Fierce Biotech

Analyst: Biosim Enbrel, Humira Won't Kill Brand Name Growth For Years
- Not all analysts share optimistic view
Biosimilars won't stop Enbrel, Humira from growing through 2022: Analyst … Never fear, makers of anti-TNF giants: Those pesky biosimilars? They won't be halting revenue growth anytime soon, Leerink Partners analysts predict …[Fierce Pharma]

Colombia Threatens  Price Control On Gleevec (imatinib mesylate)
- American threat to withhold monetary aid backfires
Colombia plans to proceed with price cut on Novartis cancer drug … may drop the price for Gleevec by up to 45 percent … Washington might withdraw support for a free trade agreement and $450 million in backing for a peace initiative between the Colombian government and Marxist rebels …[Pharmalot]

Mylan's Lawyers' Fancy Footwork Scheme To Get Epi Pen Out Of Spotlight
- Seeks to add Epi Pen to list of " federal list of preventive medical service"
- Legal loophole: copays are against the law for "preventative medical service"  products
EpiPen Maker Lobbies to Shift High Costs to Others … If the EpiPen makes the federal preventive list, most Americans would have no insurance co-pay when getting the product … would be able to continue charging high prices for the product without patients complaining about the cost. …[NY Times]
See Also: Mylan's Sneaky EpiPen Maneuvers … [Investopedia]
Editor's Comment: Great way to build trust with your stakeholders Mylan.

New Mexico Sues Sanofi, Bristol Over Plavix Marketing Tactics
- Claims marketers overstated efficacy, understated risks
Attorney General Balderas Sues Bristol-Myers Squibb For False & Deceptive Marketing … knew that its drug was ineffective in a percentage of the population and may have increased a patient's risk of internal bleeding, but the company failed to disclose … [Los Alamos Daily Post]
See Also: New Mexico AG sues Bristol-Myers, Sanofi over blood thinner … [Reuters]

Novo: Once Per Week GLP1 Reduces Cardio Risk 26%
- Differentiates Novo GLP1 stable in crowded market
- Downside? Increased rate of blindness, retinopathy complications
Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent … third diabetes drug to show such heart benefits, after Novo's Victoza injectable and Eli Lilly and Boehringer Ingelheim's Jardiance … Novo will launch a bigger and longer cardiovascular impact study for semaglutide in order to show long-term benefits …[Reuters]
Editor's Note: Novo is working on an oral version of semiglutide.

9/16 More Dangerous than ISIS and Assad
The Syrian Civil War Could Spell the End of Antibiotics .... At Médecins sans frontières's hospital in Amman, half of the patients now arrive with some sort of chronic infection; of those, 60 percent are resistant to multiple drugs. United Nations officials are so concerned they recently called for an emergency General Assembly summit on superbugs in late September .... Newsweek

9/16 Yosprala Gets FDA Nod; Aspirin + PPI
U.S. approves Aralez pill for heart patients .... Yosprala combines aspirin and omeprazole in a way that releases the omeprazole first to protect the stomach. The aspirin is then slowly released into what the company describes as a "gastroprotective zone," thus reducing the risk of stomach ulcers .... Reuters

9/16 Tesaro and Clovis 'In Play' After Medivation Sale
PARP Wars: Biotech M&A's New Hope .... Other losers in the Medivation sweepstakes seem likely to look for other options; Gilead, for example, has said it may be willing to take a risk on the right PARP inhibitor. Johnson & Johnson, always the elephant in any biopharma M&A room, already has the rights to develop Tesaro's drug to treat prostate cancer and may want to control the rest .... Bloomberg Gadfly

9/16 Trying to Get Some Clarity on FDAMA Section 114
AMCP Seeks an End to 20 Years of Confusion Over FDAMA Section 114 .... The law was supposed to give drugmakers freedom to share health care economic information about their products. Efforts to get clarity from the FDA are stepping up. .... Managed Care

9/16 (FAIR) Drug Pricing Act: Congress to Ask Pharma Companies to Show Costs and Profits for Each Drug
Senators want to force drug makers to justify big price hikes .... A bipartisan group of Senate and House members plan to introduce a bill that would force drug makers to tell the Department of Health and Human Services why any price hike of more than 10% is justified at least a month before the increase .... USA Today

9/16 Pharma is Serious About Beating California's Prop 61 — $70 Million Serious
This Vote Could Finally Make a Difference in Crazy Drug Prices .... If California's measure — which would cap how much state health programs pay for treatments at the deeply discounted level paid by the Department of Veterans Affairs — passes, it could open the floodgates in other states .... Fortune

9/16 Insulin is the Next EpiPen
A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare .... But instead of driving prices down, the competitors appear to increase prices step-by-step (which is why the price charts look like a staircase), something that's referred to as "shadow pricing." It's not just the insulin market that is doing this: The same thing happened with the EpiPen market when a competitor came in around 2013 and with multiple-sclerosis drugs .... Business Insider

9/16 South African Drugmaker Hires 700 Sales People in China
Aspen Targets Further Chinese Acquisitions After Glaxo Deal .... Aspen, which sells products such as hormones, steroids, infant formula and antiretroviral medicines in more than 150 countries, said earlier that full-year profit increased 10 percent .... Bloomberg

9/16 Opdivo Goes to Flat Dose
FDA Approves Modified Dosing Regimen for Bristol-Myers Squibb's Cancer Treatment Opdivo .... The label replaces "the single dose regimen of nivolumab (3 mg/kg intravenously every two weeks) with the new recommended regimen of 240 mg IV every two weeks until disease progression or intolerable toxicity for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer" .... Regulatory Focus

9/16 "Moneyball" Approach Predicts Drug Dangers
New Big Data Approach Predicts Drug Toxicity in Humans .... Researchers developed a computational method that analyzes data from 48 different features of a drug -- from molecular weight to details about its target -- to determine whether it would be safe for clinical use. Using machine learning, the investigators trained PrOCTOR on hundreds of U.S. Food and Drug Administration-approved drugs and drugs that failed clinical trials due to toxicity problems .... Weill Cornell

9/16 Internet Drug News Fast Takes:
FDA Warns Stores in Crackdown on E-Cigarette Sales to Minors
How tens of thousands of patients who weren't actually dying wound up on hospice care
Washington Post Wonk Blog
Company Stops Sales Of Ovarian Cancer Screening Test After FDA Warns Women Not To Use It
Costs of US prescription opioid epidemic estimated at $78.5 billion
Medical Xpress
Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial

9/15 Crops Will Be Lead Business After Bayer–Monsanto Takeover
Heroin, Nazis, and Agent Orange: Inside the $66 Billion Merger of the Year .... A combined Bayer-Monsanto would be the biggest player in an industry with only three megacompanies left standing.... Monsanto's dominance in seeds and Bayer's strength in crop chemicals means they'll be able to sell farmers a comprehensive suite of pesticides and genetically modified seeds .... Bloomberg

9/15 Shingrix Beats Zostavax in Protecting Older Patients
GSK shingles vaccine remains effective after four years .... In clinical trials, GSK's Shingrix has shown greater protection for older recipients than what has been demonstrated by Merck & Co's rival Zostavax vaccine.... The company plans to file for U.S., European and Japanese approval this year, and the vaccine could reach the market in 2017 .... Reuters

9/15 Sarepta Fans Jump on Any Scrap of Possibly Favorable News
Sarepta Soars After FDA Staffer's Exit Lifts Approval Hopes .... A U.S. Food and Drug Administration reviewer who was critical of the drugmaker's proposed treatment left the agency, potentially brightening prospects for approval of the medicine .... Bloomberg

9/15 Panel Votes to Take Black Box Off Chantix
FDA panel recommends dropping serious warning on Pfizer's Chantix .... A serious warning on Pfizer's drug that helps quit smoking should be removed, 10 of 19 independent panelists to the U.S. Food and Drug Administration recommended .... Reuters/Yahoo

9/15 Witty Takes Stock
How GlaxoSmithKline Took Its Medicine .... The maddening problem for pharmaceutical chief executives is that their tenures will be judged on the results of decisions made decades before they took command. Most of the scandals of Witty's term predated him, but so did many successes .... Matthew Herper/Forbes

9/15 Gilead Owns 58% of HIV Market; Can GSK's Tivicay Take the Lead?
You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne .... GSK is advancing a revolutionary dual HIV therapy that could give Gilead a run for its money and change the standard of care for HIV .... Motley Fool

9/15 Adam Fein, Leading Industry Guru, Takes a Deep Dive into Rebates and Channel Economics
EpiPen, Channel Economics, and the Great PBM Rebate Debate .... Will we look back on the EpiPen incident as the beginning of the end for manufacturers’ gross-to-net drug pricing models and PBMs’ traditional role in the flow of rebates? .... Drug Channels

9/15 Spectrum Can't Convince Advisory Panel that Treatment Works
Spectrum bladder cancer drug not effective: U.S. FDA panel .... Apaziquone is inserted directly into the bladder following surgery to remove tumors. In 2012, two late-stage clinical trials failed to meet their main goals .... Reuters

9/15 Analyst: Humira Sales Will Continue to Climb; Biosimilars Slow to Get Traction
Price Increases To Help Drug Hit $15 Billion In Sales .... Over the past three-and-a-half years, [Geoffrey Porges, of Leerink] writes, prices for Humira have increased, on average, by 6% every three months. The company has also been gaining market share, resulting in a tripling of sales since 2013. Enbrel has averaged a 3.5% price increase every three months, resulting in a 40% increase in sales without an increase in prescriptions .... Forbes/Matthew Herper

9/15 New Immune Globulin Approval
Cuvitru Approved for Primary Immunodeficiency .... Cuvitru is the only 20% subcutaneous immunolglobulin (IG) treatment option without proline and with the ability to infuse up to 60 mL (12 g) per site and 60 mL per hour per site as tolerated, resulting in fewer infusion sites and shorter infusion durations compared with other conventional subcutaneous IG treatments .... Pharmacy Times

9/15 Internet Drug News Fast Takes:
Pfizer Launches New "Moodivator" App to Help Support, Encourage and Motivate People with Depression
Company news release
Simone Biles Reveals She's Been Taking Medication for ADHD After Hackers Leak Her Rio Olympics Drug Test
Allergan to buy US drug developer Vitae Pharmaceuticals for $639 million
Report: Get ready for most demanding consumers in history
Drug Store News
Sex toys and the Internet of Things collide—what could go wrong?
Ars Technica

9/14 Where the EpiPen Price Hikes Went: $292.1 Million for Mylan's Top Five Executives in Past Five Years
EpiPen Maker Dispenses Outsize Pay .... Mylan, lambasted for raising prices, ranks No. 2 in U.S. drug industry in executive compensation .... WSJ

9/14 Recommended Analysis: How the Drug Pricing/Distribution Model Got So Convoluted
How Congress Can Make Drug Pricing More Rational .... The byzantine model for selling drugs isn't a concoction of business efficiency. It's the outcome of a two-decade old legal dispute that forced drug makers to try and conceal just how much they discounted off the medicines that they were selling to health plans .... Forbes/Scott Gottlieb, MD

9/14 Added Months for Ca Patients Come at High Cost
New Anticancer Drugs Up Costs and Life Expectancy Considerably .... Lifetime costs, including costs for outpatient and inpatient care increased by $72,000 for patients with breast cancer who received physician-administered drugs; for these patients, life expectancy increased by 13 months. Patients who did not receive these drugs had much smaller changes in life expectancy and costs .... HealthDay

9/14 Subsys Maker Insys, Facing Numerous Legal Issues, Spends $500,000 to Fight Legal Marijuana
A maker of deadly painkillers is bankrolling the opposition to legal marijuana in Arizona .... The campaign against marijuana legalization in Arizona received a major infusion of cash last week from a synthetic cannabis drugmaker that has been investigated for alleged improper marketing of a highly addictive prescription painkiller .... Washington Post

9/14 There's a Hole in America's Arm Where All the Money Goes
Study: Health Spending Related To Opioid Treatment Rose More Than 1,300 Percent .... From 2011 to 2015, insurers' payments to hospitals, laboratories, treatment centers and other medical providers for these patients grew from $32 million to $446 million .... Kaiser Health News

9/14 FDA Finds Balance Lacking on Cancer Websites
Skimpy risk info on cancer drug websites may give patients false hope .... For cancer drug websites oriented toward consumers, 38.5% included quantitative information about the drugs' full complement of benefits, but only 3.1% offered a numerical rundown on all the risks. For doctors, the split was even more dramatic: More than 86% of professional sites included quantitative data on the range of benefits, while just 6.2% offered similar information about the full list of risks .... Fierce Pharma

9/14 Review of DTC Ad Effects Finds Limited Impact
All that pharmaceutical advertising may be a 'mixed bag,' after all .... The analysis also found that only 1 in 10 consumers were moved by such advertising to ask a doctor for a prescription .... Stat/Pharmalot

9/14 Only 60% of Diabetics Who Should Be Getting Statins Do
Too Few Diabetes Patients Receiving Statins .... Those prescribed statins were more likely to have cardiovascular risk factors. They also were more likely to receive non-statin cholesterol-lowering therapy (28 percent, versus 13 percent for patients not receiving a statin) and had lower mean low-density lipoprotein cholesterol (90 versus 103 mg/dL) .... HealthDay

9/14 Small Group of Exploding-Price Generic Drugs Puts Dent In Part D Budget
'Extraordinary' generics price hikes hit Medicare Part D amid big reduction overall .... "Established generics"-- the 1,441 drugs that stayed on the market the entire time -- fell by just 22%. More than 300 cases of "extraordinary price increases" kept prices from falling further .... FiercePharma

9/14 "A Trail of Misuse, Addiction And Death" -- America "Awash" with Adderall
Abuse of ADHD drugs following path of opioids .... Among those 26 and older, recreational use of Adderall, an amphetamine, rose fourfold, from 345,000 people in 2006 to 1.4 million in 2014 .... Milwaukee Journal-Sentinel/Medpage Today

9/14 Internet Drug News Fast Takes:
Hospitals Jack Up Costs 'Strategically,' Study Finds
Huffington Post
Vaccine inventor raises alarm on Lyme disease
Insurers May Insist On Counseling Before Genetic Tests For Breast Cancer
Kaiser Health News
Doctors Test Drones To Speed Up Delivery Of Lab Tests
NPR Health Blog
Big Pharma Spends Millions to Keep Prices High for California Agencies
The Street

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 9/19/2016

If your intellectual property being infringed
e-mail the webmaster and we will fix it. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions. 

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!